What to Ask Before Switching to an IBD Biosimilar

Most people with inflammatory bowel disease learn about a biosimilar switch from a letter, a phone call from a specialty pharmacy, or a note at the infusion center. The decision has usually already been made by an insurer or a health system, and the conversation with your gastroenterology team happens afterward. Going into that conversation with a written list of questions to ask before switching to a biosimilar changes it from a notification into a planning session. The questions below cover the reason for the switch, the product itself, dosing and delivery, monitoring, and the response baseline worth documenting before anything changes.

What Biosimilar and Interchangeable Actually Mean

A biosimilar is a biologic medication that is highly similar to an already approved reference product with no clinically meaningful differences in safety, purity, or potency. Biosimilars are not generic copies. Biologic drugs are large proteins produced in living cells, so exact duplication is impossible, and the regulatory standard is high similarity backed by analytical, pharmacokinetic, and clinical comparison data. Product labels state this directly. The label for Inflectra confirms that infliximab-dyyb is biosimilar to Remicade, and the label for Wezlana confirms that ustekinumab-auub is biosimilar to Stelara.

Interchangeability is a separate designation. When a manufacturer supplies evidence of pharmacokinetic equivalence and safety across multiple switches, the FDA may grant interchangeable status, which allows the product to be substituted and dispensed at the pharmacy level without approval from the prescribing provider, depending on state pharmacy law. Ask which specific product you are being moved to, by its full nonproprietary name, and whether it carries that designation. The distinction determines whether your gastroenterologist has to sign off on future product changes or whether the pharmacy can make them on its own.

Questions About Why the Switch Is Happening

Ask directly whether the switch is medical or non-medical. A medical switch responds to something in your disease course, such as loss of response or an adverse reaction. A non-medical switch happens for cost or formulary reasons while your disease is stable, and it is the far more common scenario. Neither reason is a problem on its own, but the answer changes what you should watch for afterward.

Follow up by asking whether staying on the originator is an option and what it would cost you. Ask what happens if you switch and do poorly, specifically whether your plan will allow a return to the originator product and what documentation your gastroenterologist would need to request it. Ask who to contact when a shipment, prior authorization, or infusion appointment goes wrong after the change, because the specialty pharmacy handling your new product may not be the one you have been using.

What the Switching Evidence Shows

It helps to know what the research says before the conversation. The NOR-SWITCH trial, a 52-week randomized double-blind non-inferiority study, compared patients switched from originator infliximab to the biosimilar CT-P13 against patients who stayed on the originator. Its open-label extension followed 380 patients and found disease worsening in 16.8 percent of those maintained on CT-P13 versus 11.6 percent of those switched at week 52, with comparable rates of adverse events and anti-drug antibodies, concluding that switching is safe and efficacious. Exploratory analyses limited to the IBD participants, covering 155 Crohn's disease and 93 ulcerative colitis patients in the main trial, found no differences in activity indices, C-reactive protein, or fecal calprotectin between products.

Evidence on repeat switching is also reassuring. The SUSTAIN study of 237 IBD patients reported sustained clinical remission in 95.4 percent of single-switch patients and 93.6 percent of multiple-switch patients, with no treatment discontinuations in either group. The 2025 ACG clinical guideline update for ulcerative colitis states that biosimilars to anti-tumor necrosis factor therapies and to ustekinumab are acceptable substitutes for originator therapies and that delays in switching should not occur.

Questions About Dosing, Delivery, and Monitoring

Ask whether your dose and schedule change. Usually they do not. Inflectra is dosed at 5 mg/kg intravenously at weeks 0, 2, and 6, then every 8 weeks, matching the originator schedule, and Wezlana uses a single weight-based intravenous induction of 260 to 520 mg followed by 90 mg subcutaneously every 8 weeks. If you have been on a dose-escalated regimen such as every six weeks or a higher weight-based dose, confirm in writing that the escalation carries over. Ask about device differences too, since pen grip, needle gauge, citrate content, and refrigeration requirements vary between adalimumab products even when the drug and dose match. The Cyltezo label covers the same adult Crohn's disease and ulcerative colitis indications as its reference product.

Then ask what monitoring happens after the switch and when. A reasonable request is objective testing at roughly the same interval you would normally have, plus a check a few months out. AGA guidance for both Crohn's disease and ulcerative colitis supports combining biomarkers with symptoms rather than relying on symptoms alone, using fecal calprotectin below 150 micrograms per gram and C-reactive protein below 5 milligrams per liter as markers of inactive inflammation. Ask whether trough drug levels and anti-drug antibody testing will be checked, since those results distinguish a true pharmacologic problem from other causes of new symptoms.

Documenting Your Baseline Before the Switch

The most useful thing you can do before the switch date is record where you actually stand on the current product. Write down your recent symptom pattern, your most recent calprotectin and CRP values with their dates, any trough level you have had, your current dose and interval, and any infusion or injection reactions. Without that record, every symptom in the months after the switch becomes an argument about memory.

This matters because expectation influences reported outcomes. A study of non-medical switching to biosimilar infliximab in IBD found significantly worse perceived disease control at week 16 in switched patients, a difference that had resolved by week 32, while objective biomarkers stayed stable. A review of infliximab biosimilar switching practices recommends proactive patient education, adequate lead time for provider discussion, and involvement of pharmacists and infusion nurses to give patients balanced information about the benefit-risk profile. Objective baseline data lets your care team separate a nocebo response, which usually settles, from genuine loss of response, which needs action. Bring the questions and the baseline to the same appointment, and the switch becomes a documented step in your treatment history rather than a gap in it.